(redirected from ribozyme)
Also found in: Dictionary, Medical, Encyclopedia, Wikipedia.
RBZReserve Bank of Zimbabwe
RBZRegionaal Bureau Zelfstandigen (Dutch public assistance office)
RBZRiparian Buffer Zone (biodiversity)
RBZReichsbahnzentrale (German)
RBZRoth, Bookstein and Zaslow LLP (Los Angeles, CA)
References in periodicals archive ?
The result: an 83-nucleotide ribozyme that was only moderately sequence-specific and could reliably knit a test segment of left-handed RNA to a template -- about a million times faster than would have happened without enzyme assistance.
But to do their work, ribozymes need to first get into the cells, and for that they need help.
Correct insertion of the ribozyme in the resulting plasmids pVif5113 and pVif5113A was verified by sequencing.
A biochemist, Breaker has worked on synthetic ribozymes for many years.
Like protein-based enzymes, ribozyme catalysis obeys Michaelis-Menten principles, with some exceptions.
Ribozyme is partnered with Chiron Corporation (Emeryville, CA) for the development and commercialization of ANGIOZYME, an anti-angiogenic ribozyme designed to inhibit the growth of new vasculature to supply blood to tumors and prevent tumor growth and metastasis, which is also in two Phase II clinical trials.
Bashkin's find could lead to cheaper chemotherapy drugs that produce far fewer side effects because his ribozyme mimics recognize the chemistry of dangerous mRNA, leaving the normal mRNA alone.
The research team found a theoretical explanation for why the Diels-Alder ribozyme needs magnesium to function.
This paper describes cloning of an anti-HIV hammerhead ribozyme Tat5910 into the retroviral vector, pSuper.
Cambridge, MA; 617-679-5500) announced the issuance of a United States patent that contains broad claims covering ribozymes with 2'-O-methyl modifications.
The purpose of this experiment was to design and synthesize a catalytic hammerhead ribozyme targeted to the GUA target site located at nucleotide 8618 NL43 HIV Rev gene.
Ribozyme also announced that it has exclusively licensed nucleic acid-based technologies from Yale University (New Haven, CT) to further strengthen its intellectual property portfolio.